summit therapeutics astrazeneca

News

Summit, AstraZeneca and Lung cancer

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Medical Dialogues · 2d

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a deal that could be worth up to USD 15 billion, according to a

Investopedia on MSN · 3d

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Yahoo Finance3d

Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal - Yahoo Finance

Investing.com -- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for ...

3don MSN

Why AstraZeneca Stock Got Thumped on Thursday

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

pharmaphorum2d

Summit climbs on rumour of $15bn AstraZeneca interest

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results